文献速递免疫规划卫生政策与健康促进

世界卫生组织针对婴儿呼吸道合胞病毒病被动免疫单克隆抗体的首选产品特性:全球应用的关键考量

WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use.
PubMed 文献 · Vaccine · 2022-02-17

世界卫生组织(WHO)发布了针对婴儿严重呼吸道合胞病毒(RSV)疾病被动免疫单克隆抗体的首选产品特性,关注中低收入国家的全球公共卫生需求。本文总结了该首选产品特性的关键属性,并讨论了未来获取和使用预防性RSV单克隆抗体的关键考量。

要点

  • WHO首选产品特性描述有助于优化价值和全球使用的产品属性,尤其关注中低收入国家。
  • WHO此前已发布孕产妇和儿科RSV疫苗的首选产品特性,近期发布了婴儿用单克隆抗体的首选产品特性。
  • 本文总结了该首选产品特性的关键属性,并讨论了未来获取和使用预防性RSV单克隆抗体的关键考量。

核心结论

  • WHO发布了针对婴儿严重RSV疾病被动免疫单克隆抗体的首选产品特性,以指导产品开发并优化全球公共卫生价值,尤其关注中低收入国家。

研究设计与样本

  • 本文为对WHO首选产品特性文件的总结与讨论,梳理了婴儿用RSV单克隆抗体的关键产品属性及全球应用考量。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

World Health Organization (WHO) preferred product characteristics describe preferences for product attributes that would help optimize value and use to address global public health needs, with a particular focus on low- and middle-income countries. Having previously published preferred product characteristics for both maternal and paediatric respiratory syncytial virus (RSV) vaccines, WHO recently published preferred product characteristics for monoclonal antibodies to prevent severe RSV disease in infants. This article summarizes the key attributes from the preferred product characteristics and discusses key considerations for future access and use of preventive RSV monoclonal antibodies.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Sparrow E, Adetifa I, Chaiyakunapruk N, et al. WHO preferred product characteristics for monoclonal antibodies for passive immunization against respiratory syncytial virus (RSV) disease in infants - Key considerations for global use. Vaccine. 2022. PMID: 35184927. doi:10.1016/j.vaccine.2022.02.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。